MYRIAD GENETICS, INC. Key Metrics

2 years of history · ending 2024-12-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-1
Book Value Per Share
$8
Free Cash Flow Per Share
$-0
Cash Per Share
$1
Revenue Per Share
$9
OCF Per Share
$-0
Return on Equity
-17.2%
Return on Assets
-11.7%
Return on Invested Capital
-12.5%
Debt to Equity
0.06
Current Ratio
1.82
Quick Ratio
1.65
Asset Turnover
0.77
Days Sales Outstanding
52.82
Days Payables Outstanding
46.75
Days Inventory On Hand
39.80
Cash Conversion Cycle
45.87
R&D / Revenue
13.5%
SBC / Revenue
5.9%
Capex / Revenue
Working Capital
$134M
Net Current Asset Value
$-29M
Invested Capital
$741M
OCF / Net Income
0.07
FCF / Net Income
0.07
Accruals Ratio (Sloan)
-11.5%
Net Debt
$-63M
Net Debt / EBITDA
1.01
Interest Coverage
-44.11
Cash Coverage
-3.11
Capex Coverage
Tangible Common Equity
$152M
TCE / Total Assets
14.8%
Goodwill / Total Assets
27.9%
NOPAT
$-98M
Cash ROIC
-1.1%
WC / Revenue
16.0%
Capex / D&A
Reinvestment Rate
49.6%
Total Payout Ratio
Asset Growth vs Revenue Growth
-21.6%
Revenue 5Y CAGR
5.6%
EPS 5Y CAGR
FCF 5Y CAGR
EBITDA 5Y CAGR
Book Value 5Y CAGR
-5.3%
Stock Price (FY-end)
$14
Market Cap
$1.24B
P/E Ratio
P/S Ratio
1.48
P/B Ratio
1.77
P/TB Ratio
8.15
P/OCF Ratio
P/FCF Ratio
Enterprise Value
$1.18B
EV / EBITDA
EV / Sales
1.41
EV / FCF
FCF Yield
-0.7%
Shareholder Yield
-4.0%
Buyback Yield
R&D Yield
9.1%
Capex Yield
Operating Leverage
Graham Number
Shares Variation (YoY)
9.4%
Beta (5Y)
1.33
Cost of Equity
11.1%
Cost of Debt (after tax)
5.6%
WACC
ROIC - WACC Spread
52W High
$29
52W Low
$13
Trailing Return 1Y
-28.4%
Trailing Return 5Y
-48.8%
F-Score (Piotroski)
4.00
Z-Score (Altman)
1.83

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Beat / Miss vs Estimate

Stock Price on Earnings Dates

MYRIAD GENETICS, INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes-1.80%3.20%2.30%1.60%1.90%-0.10%
Foreign Rate Differential-0.30%-0.90%0.00%0.20%-2.70%0.00%
Other Adjustments-0.30%-1.40%0.90%-0.70%-0.70%-0.90%
R&D Tax Credits-1.30%4.40%-2.50%-0.60%-0.30%
SBC (Nondeductible)0.10%
Valuation Allowance Change-1.70%5.60%-1.80%-20.10%-12.70%
Effective Tax Rate10.60%52.30%20.30%-0.40%-3.10%7.40%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)−$23.7M−$29.9M−$28.6M$1.1M$3.8M−$29.2M
Income Taxes Paid (Cash)